0000000000140978

AUTHOR

Morisco F.

showing 2 related works from this author

Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.

2014

Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Background & Aims: Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to …

Malemedicine.medical_specialtyPediatricsCarcinoma HepatocellularTime FactorsHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIADiseaseGastroenterologyBiasInternal medicineOverall survivalmedicineHumansEarly Detection of CancerAgedEstimationSurveillanceHepatologybusiness.industryLiver Neoplasmsmedicine.diseasedigestive system diseasesLead time biasCirrhosisHepatocellular carcinomaFemalebusinessLead-time biasFollow-Up Studies
researchProduct

Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study

2009

The aim of the study was to evaluate the characteristics of chronic hepatitis B with special reference to the geographical origin of the patients and to the prevalence of HBeAg and viral and non-viral co-factors of liver disease. A cross-sectional multicenter survey was undertaken, which enrolled 1,386 HBsAg chronic carriers observed consecutively in 21 referral centers over a 6-month period. The prevalence of HBeAg in patients was 11%; the presence of HBeAg was associated independently with a younger age and co-infection with HIV. Anti-HDV, anti-HCV, or anti-HIV antibodies were detected in 8.1%, 6.5%, and 2%, respectively. However, among the patients first diagnosed during the study period…

MaleHBsAgvirusesHIV InfectionsAntibodies ViralHBeAgHepatitisLiver diseaseCHRONIC HEPATITIS B; HBsAg; epidemiology; GEOGRAPHICAL LANDSCAPEHBsAg0302 clinical medicine80 and overPrevalenceViralChronicAged 80 and over0303 health sciencesGeographyAge Factorsvirus diseasesHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis D3. Good healthInfectious DiseasesHBeAgCirrhosisItalyMedicineepidemiology030211 gastroenterology & hepatologyFemaleHepatitis D virusHumanAdultHepatitis Viral HumanAdolescentCHRONIC HEPATITIS BAntibodies03 medical and health sciencesHepatitis B ChronicHDVVirologyCirrhosis HBeAg HDV Hepatitis B Adolescent Adult Age Factors Aged Aged 80 and over Antibodies Viral Cross-Sectional Studies Female Geography HIV HIV Infections Hepatitis B Chronic Hepatitis Viral Human Humans Italy Male Middle Aged Prevalence Virology Infectious DiseasesmedicineCirrhosis; HBeAg; HDV; Hepatitis B; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Cross-Sectional Studies; Female; Geography; HIV; HIV Infections; Hepatitis B Chronic; Hepatitis Viral Human; Humans; Italy; Male; Middle Aged; Prevalence; Infectious Diseases; VirologyHumans030304 developmental biologyAgedHepatitisCirrhosibusiness.industryHIVmedicine.diseaseVirologydigestive system diseasesCross-Sectional StudiesGEOGRAPHICAL LANDSCAPEbusiness
researchProduct